Clinical oncology and cancer treatmentprimary
3 projects
All three H2020 projects (NANOFACTURING, DiaChemo, PREFER) directly relate to cancer treatment, drug monitoring, or patient outcomes in oncology settings.
Organization
INSTITUTO TUMORI "GIOVANNI PAOLO II"
Italian cancer research hospital (IRCCS) contributing clinical oncology expertise to EU projects in nanomedicine, diagnostics, and patient-centered drug assessment.
Research institutehealthITNo active H2020 projectsThin data (2/5)
H2020 projects
3
As coordinator
0
Total EC funding
€343K
Unique partners
53
What they do
Their core work
IRCCS Bari is a publicly recognized clinical cancer research hospital (IRCCS designation) in southern Italy, specializing in oncology diagnosis, treatment, and translational research. In H2020 projects, they contributed clinical oncology expertise to technology development — from nanomedicine manufacturing scale-up to point-of-care diagnostics for chemotherapy monitoring. Their role bridges the gap between laboratory innovation and real clinical cancer care, providing patient access, clinical validation environments, and oncological domain knowledge to multi-partner research consortia.
Core expertise
What they specialise in
Point-of-care diagnostics for chemotherapysecondary
1 project
DiaChemo focused on microfluidic devices for quantifying chemotherapeutic drugs in small body fluid samples — a direct clinical need in oncology wards.
Nanomedicine clinical validationsecondary
1 project
NANOFACTURING addressed sustainable manufacturing of clinically relevant nanomaterials, where IRCCS Bari likely provided clinical trial or validation expertise.
Patient-reported outcomes and drug benefit-riskemerging
1 project
PREFER examined patient preferences in benefit-risk assessments during the drug lifecycle, contributing the patient and clinical perspective.
Evolution & trajectory
How they've shifted over time
Early focus
Cancer diagnostics and nanomedicine
Recent focus
Patient-centered drug assessment
With all projects starting in 2015-2016, IRCCS Bari's H2020 participation was concentrated in a narrow window rather than showing a clear evolution over time. Their earliest projects (NANOFACTURING, DiaChemo) focused on technology-driven cancer diagnostics and treatment tools, while the slightly later PREFER project shifted toward patient-centered drug assessment — suggesting a broadening from purely technical contributions toward regulatory and patient-outcome dimensions. However, with only three projects and no activity after 2016, drawing strong trend conclusions would be speculative.
Their trajectory hints at expanding from clinical technology validation toward patient preference and regulatory science, though limited data makes this tentative.
Collaboration profile
How they like to work
Role: specialist_contributorReach: European12 countries collaborated
IRCCS Bari has exclusively participated as a partner, never leading a consortium — consistent with a clinical institution contributing domain expertise rather than driving large-scale research agendas. With 53 unique partners across just 3 projects, they operate in large, multi-partner consortia typical of health-sector RIA projects. This profile suggests they are a reliable clinical endpoint partner: easy to integrate, accustomed to large teams, and focused on delivering clinical input rather than competing for coordination.
Despite only three projects, IRCCS Bari has collaborated with 53 unique partners across 12 countries, reflecting participation in large European health research consortia with broad geographic diversity.
Why partner with them
What sets them apart
As an IRCCS-designated cancer hospital, they hold a specific status in the Italian research system — recognized by the Ministry of Health as combining clinical care with scientific research. This gives them direct access to oncology patients, clinical data, and treatment workflows that purely academic partners cannot offer. For consortium builders needing a clinical oncology site in southern Italy with experience in EU collaborative projects, they fill a well-defined niche.
Notable projects
Highlights from their portfolio
- NANOFACTURINGLargest EC contribution (€187K) and an unusual cross-sector project bridging manufacturing scale-up with clinical nanomedicine applications.
- DiaChemoDirectly addresses a real clinical pain point — real-time monitoring of chemotherapy drug levels at the bedside using microfluidic technology.
- PREFERIMI-linked project (Sofia ref.) on patient preferences in drug assessment, connecting IRCCS Bari to the pharmaceutical regulatory ecosystem.
Cross-sector capabilities
Manufacturing — clinical validation of nanomedicine production processesDiagnostics — point-of-care device testing in real hospital environmentsRegulatory science — patient preference data for drug lifecycle decisions
More in Health & Biomedical
See all Health & Biomedical organizations →KOBENHAVNS UNIVERSITET
Denmark's largest research university, excelling in genomics, CRISPR, microbiome science, ancient DNA, and climate research across 696 H2020 projects.
Open →
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France's national biomedical research agency — 400+ H2020 projects spanning neuroscience, infectious disease, cancer, and omics-driven diagnostics.
Open →
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Germany's leading research university in molecular biosciences and translational medicine, with 303 H2020 projects and exceptional ERC grant concentration.
Open →